Zastosowanie wolno działających leków objawowych w chorobie zwyrodnieniowej stawów. Skuteczność połączenia glukozaminy z chondroityną w świetle dowodów Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2021
Słowa kluczowe:
choroba zwyrodnieniowa stawów, chrząstka, celekoksyb, siarczan chondroityny, chlorowodorek glukozaminy, bezpieczeństwo
##plugins.themes.bootstrap3.article.main##
Abstrakt
Leczenie choroby zwyrodnieniowej stawów wymaga zastosowania leków, które pozwolą na spowolnienie destrukcji chrząstki stawowej oraz ograniczenie bólu stawów. W codziennej praktyce często stosowane są wolno działające leki objawowe. Do najczęściej stosowanych i uważanych za najskuteczniejsze zalicza się preparaty glukozaminy i chondroityny. Wysokiej jakości badania wykazały, że połączenie obu tych substancji jest skuteczne w zakresie spowolnienia postępu choroby i zmniejszania nasilenia bólu, a także bezpieczne, nawet przy długotrwałym stosowaniu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Tłustochowicz , W. (2021). Zastosowanie wolno działających leków objawowych w chorobie zwyrodnieniowej stawów. Skuteczność połączenia glukozaminy z chondroityną w świetle dowodów. Medycyna Faktów , 14(1(50), 110-115. https://doi.org/10.24292/01.MF.0121.15
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Scanzello C, Plaas A, Crow M. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound? Curr Opin Rheumatol. 2008; 20: 565-72.
2. Managing osteoarthritis. NICE Pathway. Updated: 11 December 2020.
3. Haugen I, Englund M, Aliabadi P et al. Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study. Ann Rheum Dis. 2011; 70: 1581-6. http://doi.org/10.1136/ard.2011.150078.
4. Klimiuk PA, Kuryliszyn-Moskal A. Choroba zwyrodnieniowa stawów. In: Puszczewicz M. Wielka interna – reumatologia. 2nd ed. Medical Tribune Polska, Warszawa 2016.
5. Bos S, Slagboom P, Meulenbelt I. New insights into osteoarthritis: early developmental features of an ageing-related disease. Curr Opin Rheumatol. 2008; 20: 553-9.
6. Zhang W, Doherty M, Peat G et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010; 69: 483-9.
7. Sakellariou G, Conaghan PG, Zhang W et al. EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis. Ann Rheum Dis. 2017; 76(9): 1484-94.
8. Lotz M, Martel-Pelletier J, Christiansen C et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis. 2013; 72: 1756-63.
9. Pottie B, Presle N, Terlain B et al. Obesity and osteoarthritis: more complex than predicted! Ann Rheum Dis. 2006; 65(11): 1403-5.
10. Bruyere O, Honvo G, Veronese N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49(3): 337-50.
11. da Costa BR, Reichenbach S, Keller N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017; 390(10090): e21-33.
12. Kolasinski S, Neogi T, Hochberg M et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020; 72(2): 149-62. http://doi.org/10.1002/acr.24131.
13. Kloppenburg M, Kroon FP, Blanco FJ et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019; 78(1): 16-24.
14. Bannuru R, Osani M, Vaysbrot E et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019; 27(11): 1578-89.
15. Oo WM, Hunter DJ. Disease modification in osteoarthritis: are we there yet? Clin Exp Rheumatol. 2019; 37 suppl 120(5): 135-40.
16. Calamia V, Mateos J, Fernández-Puente P et al. A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine. Sci Rep. 2014; 4: 5069. http://doi.org/10.1038/srep05069.
17. Reginster J-Y, Dudler J, Blicharski T et al. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017; 76(9): 1537-43. http://doi.org/10.1136/annrheumdis-2016-210860.
18. McAlindon T, LaValley M, Gulin J et al. Glucosamine and Chondroitin for Treatment of Osteoarthritis. A Systematic Quality Assessment and Meta- analysis. JAMA. 2000; 283(11): 1469-75. http://doi.org/10.1001/jama.283.11.1469.
19. Reginster J-Y, Deroisy R, Rovati L et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001; 357(9252): 251-6.
20. Bruyere O, Pavelka K, Rovati L et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2008; 16(2): 254-60.
21. Clegg D, Reda D, Harris C et al. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. N Engl J Med. 2006; 354(8): 795-808.
22. Hochberg M, Martel-Pelletier J, Monfort J et al; on behalf of the MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016; 75(1): 37-44. http://doi.org/10.1136/annrheumdis-2014-206792.
23. Fransen M, Agaliotis M, Nairn L et al; on behalf of the LEGS study collaborative group: Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015; 74(5): 851-8. http://doi.org/10.1136/annrheumdis-2013-203954.
2. Managing osteoarthritis. NICE Pathway. Updated: 11 December 2020.
3. Haugen I, Englund M, Aliabadi P et al. Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study. Ann Rheum Dis. 2011; 70: 1581-6. http://doi.org/10.1136/ard.2011.150078.
4. Klimiuk PA, Kuryliszyn-Moskal A. Choroba zwyrodnieniowa stawów. In: Puszczewicz M. Wielka interna – reumatologia. 2nd ed. Medical Tribune Polska, Warszawa 2016.
5. Bos S, Slagboom P, Meulenbelt I. New insights into osteoarthritis: early developmental features of an ageing-related disease. Curr Opin Rheumatol. 2008; 20: 553-9.
6. Zhang W, Doherty M, Peat G et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010; 69: 483-9.
7. Sakellariou G, Conaghan PG, Zhang W et al. EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis. Ann Rheum Dis. 2017; 76(9): 1484-94.
8. Lotz M, Martel-Pelletier J, Christiansen C et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis. 2013; 72: 1756-63.
9. Pottie B, Presle N, Terlain B et al. Obesity and osteoarthritis: more complex than predicted! Ann Rheum Dis. 2006; 65(11): 1403-5.
10. Bruyere O, Honvo G, Veronese N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49(3): 337-50.
11. da Costa BR, Reichenbach S, Keller N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017; 390(10090): e21-33.
12. Kolasinski S, Neogi T, Hochberg M et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020; 72(2): 149-62. http://doi.org/10.1002/acr.24131.
13. Kloppenburg M, Kroon FP, Blanco FJ et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019; 78(1): 16-24.
14. Bannuru R, Osani M, Vaysbrot E et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019; 27(11): 1578-89.
15. Oo WM, Hunter DJ. Disease modification in osteoarthritis: are we there yet? Clin Exp Rheumatol. 2019; 37 suppl 120(5): 135-40.
16. Calamia V, Mateos J, Fernández-Puente P et al. A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine. Sci Rep. 2014; 4: 5069. http://doi.org/10.1038/srep05069.
17. Reginster J-Y, Dudler J, Blicharski T et al. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017; 76(9): 1537-43. http://doi.org/10.1136/annrheumdis-2016-210860.
18. McAlindon T, LaValley M, Gulin J et al. Glucosamine and Chondroitin for Treatment of Osteoarthritis. A Systematic Quality Assessment and Meta- analysis. JAMA. 2000; 283(11): 1469-75. http://doi.org/10.1001/jama.283.11.1469.
19. Reginster J-Y, Deroisy R, Rovati L et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001; 357(9252): 251-6.
20. Bruyere O, Pavelka K, Rovati L et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2008; 16(2): 254-60.
21. Clegg D, Reda D, Harris C et al. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. N Engl J Med. 2006; 354(8): 795-808.
22. Hochberg M, Martel-Pelletier J, Monfort J et al; on behalf of the MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016; 75(1): 37-44. http://doi.org/10.1136/annrheumdis-2014-206792.
23. Fransen M, Agaliotis M, Nairn L et al; on behalf of the LEGS study collaborative group: Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015; 74(5): 851-8. http://doi.org/10.1136/annrheumdis-2013-203954.